CD8A and neoplasm: So far, these results imply that PLK1 protein can be used as a shared tumour antigen and PLK1122 is the most effective peptide in generating CD8 T-cells capable of recognising numerous PLK1-expressing tumour cells, resulting in potent therapeutic anti-tumour effects.